NEKTAR THERAPEUTICS
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Josh GottheimerHouse · D · NJ |
NKTRNEKTAR THERAPEUTICS · Stock |
Sale $1,001 - $15,000 |
Oct 2, 2018 | Jun 21, 2018 | Filing ↗ |
Josh GottheimerHouse · D · NJ |
NKTRNEKTAR THERAPEUTICS · Stock |
Purchase $1,001 - $15,000 |
Oct 2, 2018 | Jun 6, 2018 | Filing ↗ |
Eric SwalwellHouse · D · CA |
NKTRNEKTAR THERAPEUTICS · Stock |
Sale $1,001 - $15,000 |
Apr 7, 2015 | Apr 1, 2015 | Filing ↗ |
Eric SwalwellHouse · D · CA |
NKTRNEKTAR THERAPEUTICS · Stock |
Sale $1,001 - $15,000 |
Feb 27, 2015 | Jan 31, 2015 | Filing ↗ |
Whale Activity
- Increased88
- New34
- Held38
- Decreased68
- Closed38
- No prior filing14
| Filer | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 5.1M | $310.1M | increased |
| Two Seas Capital LP | 3.3M | $202.6M | increased |
| BlackRock, Inc. | 2.9M | $173.9M | decreased |
| BVF INC/IL | 2.1M | $129.2M | decreased |
| STATE STREET CORP | 1.8M | $107.3M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | $90.9M | increased |
| TWO SIGMA INVESTMENTS, LP | 1.2M | $73.2M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 891.9K | $54.0M | increased |
| MORGAN STANLEY | 830.2K | $50.3M | decreased |
| Prosight Management, LP | 785.0K | $47.5M | decreased |
| ARMISTICE CAPITAL, LLC | 700.0K | $42.4M | decreased |
| GOLDMAN SACHS GROUP INC | 621.2K | $37.6M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| ROBIN HOWARD WPresident & CEO · Director | Sale | −429 | $35.85 | $15K | Nov 17, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −192 | $35.85 | $7K | Nov 17, 2026 | Form 4 ↗ |
| WHITFIELD ROY ADirector | Grant / award | +2,000 | $0.00 | $0 | Sep 23, 2026 | Form 4 ↗ |
| GREER R SCOTTDirector | Grant / award | +2,000 | $0.00 | $0 | Sep 23, 2026 | Form 4 ↗ |
| CHESS ROBERTDirector | Grant / award | +2,000 | $0.00 | $0 | Sep 23, 2026 | Form 4 ↗ |
| Brainard DianaDirector | Grant / award | +2,000 | $0.00 | $0 | Sep 23, 2026 | Form 4 ↗ |
| Ajer Jeffrey RobertDirector | Grant / award | +2,000 | $0.00 | $0 | Sep 23, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −186 | $71.98 | $13K | Aug 18, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −418 | $71.98 | $30K | Aug 18, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −5,681 | $70.00 | $398K | Jun 30, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −4,500 | $61.65 | $277K | Jun 17, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −5,500 | $60.81 | $334K | Jun 17, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −4,697 | $60.71 | $285K | Jun 16, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −5,303 | $59.97 | $318K | Jun 16, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −5,538 | $60.71 | $336K | Jun 15, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −199 | $65.51 | $13K | May 19, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −444 | $65.51 | $29K | May 19, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −180 | $73.00 | $13K | Feb 18, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −423 | $73.00 | $31K | Feb 18, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −3,867 | $35.67 | $138K | Jan 20, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust | 1.9M | $132.1M | 0.14% | Aug 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $75.1M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 896.1K | $62.6M | 0.08% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund Fidelity Mt. Vernon Street Trust | 500.4K | $35.7M | 0.13% | Aug 31, 2026 |
| Fidelity Series Growth Company Fund Fidelity Mt. Vernon Street Trust | 424.6K | $30.3M | 0.12% | Aug 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 387.6K | $27.1M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 376.9K | $26.6M | 0.08% | Jul 31, 2026 |
| LORD ABBETT DEVELOPING GROWTH FUND INC LORD ABBETT DEVELOPING GROWTH FUND, INC. | 273.9K | $23.3M | 1.05% | Apr 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 285.3K | $19.9M | 0.13% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 197.5K | $14.1M | 0.08% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list NKTR's shares (CUSIP 640268306), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 1.8M shares5.2%
Nov 10, 2026 · ↗ - Sina ToussiSCHEDULE 13G/A · passive (13G) · 3.3M shares9.8%
Sep 28, 2026 · ↗ - Two Seas Capital GP LLCSCHEDULE 13G/A · passive (13G) · 3.3M shares9.8%
Sep 28, 2026 · ↗ - Two Seas Capital LPSCHEDULE 13G/A · passive (13G) · 3.3M shares9.8%
Sep 28, 2026 · ↗ - Sina ToussiSCHEDULE 13G/A · passive (13G) · 3.1M shares9.1%
Aug 14, 2026 · ↗ - Two Seas Capital GP LLCSCHEDULE 13G/A · passive (13G) · 3.1M shares9.1%
Aug 14, 2026 · ↗ - Two Seas Capital LPSCHEDULE 13G/A · passive (13G) · 3.1M shares9.1%
Aug 14, 2026 · ↗ - BVF INC/ILSCHEDULE 13G/A · passive (13G) · 2.4M shares7.1%
Aug 14, 2026 · ↗ - BVF PARTNERS L P/ILSCHEDULE 13G/A · passive (13G) · 2.4M shares7.1%
Aug 14, 2026 · ↗ - BVF GP HOLDINGS LLCSCHEDULE 13G/A · passive (13G) · 2.2M shares6.5%
Aug 14, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming NEKTAR THERAPEUTICS as the client.
- BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2022 Q2 · HCR—
Filing ↗ - BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2022 Q1 · HCR$50K
Filing ↗ - BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2021 Q4 · HCR$50K
Filing ↗ - BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2021 Q3 · HCR$50K
Filing ↗ - BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2021 Q2 · HCR$50K
Filing ↗
Government Contracts
No federal contract awards found for NEKTAR THERAPEUTICS.
U.S. Patents
No USPTO patent applications found for NEKTAR THERAPEUTICS.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M |
| Operating income | -$140.1M | -$105.2M | -$263.7M | -$376.2M | -$446.1M |
| Net income | -$164.1M | -$119.0M | -$276.1M | -$368.2M | -$523.8M |
| Diluted EPS | -$9.73 | -$8.68 | -$1.45 | -$1.97 | -$2.86 |
| Operating cash flow | -$208.5M | -$175.7M | -$192.6M | -$304.0M | -$412.7M |
| Cash and equivalents | $15.1M | $44.3M | $35.3M | $88.2M | $25.2M |
| Total assets | $280.4M | $303.9M | $398.0M | $710.6M | $1.12B |
| Total liabilities | $190.6M | $243.1M | $267.0M | $344.0M | $437.7M |
| Shareholders' equity | $89.8M | $60.7M | $131.0M | $366.6M | $679.5M |
As NEKTAR THERAPEUTICS tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 13, 2026 ↗
Stock Splits
- 1-for-15Reverse splitJun 9, 2025
- 2-for-1Stock splitAug 23, 2000
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 7.01Reg FD disclosureNov 13, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureOct 1, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 25, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 13, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 5, 2026
EDGAR ↗ - 8-K · Items 1.01, 5.02, 9.01Material agreement · Officer / director changeMay 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗


